Delcath’s Chemotherapy Device Has Risks, FDA Staff SaysAnna Edney
Delcath Systems Inc.’s experimental drug-and-device combination for chemotherapy carries life-threatening risks that may outweigh any benefit, U.S. Food and Drug Administration staff said. The shares fell the most in more than five years .
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.